Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and purpose</h3><p>Increasing evidence suggests that human cholestasis is closely associated with the accumulation and activation of hepatic macrophages. Research indicates that activation of peroxisome proliferator‐activated receptor‐γ (PPARγ) exerts liver protective effects in cholestatic liver disease (CLD), particularly by ameliorating inflammation and fibrosis, thus limiting disease progression. However, the existing PPARγ agonists, such as troglitazone and rosiglitazone, have significant side effects that impede their clinical application in the treatment of CLD. In this study, we found that tectorigenin (TEC) alleviates intrahepatic cholestasis in mice by activating PPARγ.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental approach</h3><p>Wild‐type mice were intragastrically administered α‐naphthylisothiocyanate (ANIT) or fed a diet containing 0.1% 3,5‐diethoxycarbonyl‐1,4‐dihydrocollidine (DDC) to simultaneously establish an experimental model of intrahepatic cholestasis and TEC intervention, followed by determination of intrahepatic cholestasis and the mechanisms involved. In addition, PPARγ‐deficient mice were administered ANIT and/or TEC to determine whether TEC exerts its liver protective effect by activating PPARγ.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key results</h3><p>We demonstrated that TEC intervention alleviated intrahepatic cholestasis by inhibiting the recruitment and activation of hepatic macrophages as well as by promoting the expression of bile transporters via activation of PPARγ. Furthermore, our results show that TEC increased bile salt export pump (BSEP) expression through enhanced PPARγ binding to the <i>BSEP</i> promoter. We also demonstrated that PPARγ deficiency blocked the hepatoprotective effect of TEC during cholestasis. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions and implications</h3><p>In conclusion, TEC reduced the recruitment and activation of hepatic macrophages, and enhanced the export of bile acids by activating PPARγ. Taken together, our results suggest that TEC is a candidate compound for cholestasis treatment.</p></section>

Elevated Concentrations of 15‐deoxy‐δ12,14‐prostaglandin J2 in Chronic Liver Disease Propose Therapeutic Trials with Peroxisome Proliferator Activated Receptor Γ‐inducing Drugs

Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor α agonists

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

The impact of CHIP on children's insurance coverage: an analysis using the National Survey of America's Families.

PPAR Gamma Inhibits Growth of Rat Hepatic Stellate Cells and TGF Beta-Induced Connective Tissue Growth Factor Expression

Protein extracts of Crassostrea gigas alleviate CCl₄-induced hepatic fibrosis in rats by reducing the expression of CTGF, TGF-β1 and NF-κB in liver tissues.

15-keto-PGE2 alleviates nonalcoholic steatohepatitis through its covalent modification of NF-κB factors

15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors

Tectorigenin alleviates intrahepatic cholestasis by inhibiting hepatic inflammation and bile accumulation via activation of PPAR

The Rationale for Targeting Tgf-Beta in Chronic Liver Diseases

Pioneering PGC-1α–boosted secretome: a novel approach to combating liver fibrosis

Up-regulation of Nrf2/P62/Keap1 involves in the anti-fibrotic effect of combination of monoammonium glycyrrhizinate and cysteine hydrochloride induced by CCl4

Tectorigenin alleviates intrahepatic cholestasis by inhibiting hepatic inflammation and bile accumulation via activation of PPARγ

The Active Constituent From Gynostemma Pentaphyllum Prevents Liver Fibrosis Through Regulation of the TGF-β1/NDRG2/MAPK Axis

A PIK3CA pyrosequencing-based assay that excludes pseudogene interference.

15-deoxy-Δ12,14-prostaglandin J2 relieved acute liver injury by inhibiting macrophage migration inhibitory factor expression via PPARγ in hepatocyte

Effect of prostaglandin E2 and prostaglandin I2 on PDGF-induced proliferation of LI90, a human hepatic stellate cell line

PPARγ Ligands Inhibit Cholangiocarcinoma Cell Growth Through P53-Dependent GADD45 and P21waf1/cip1 Pathway

The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model

Comprehensive phospholipid and sphingomyelin profiling of different brain regions in mouse model of anxiety disorder using online two‐dimensional (HILIC/RP)‐LC/MS method

Cpd861 Targeting BCL2 to Alleviate Hepatic Fibrosis: Network Pharmacology, Mendelian Randomization, and Molecular Docking Mechanisms